As leaders in the field of epigenetics, we continue to contribute to the scientific understanding of this important therapeutic space by sharing our findings in peer reviewed publications in leading life science academic journals. We also share our data with the scientific community at global conferences in the form of posters and oral presentations. Highlighted below are some of our recent publications and key articles that continue to build upon the progress of science in this field.


Atherosclerosis 2018
Apabetalone downregulates factors and pathways associated with vascular calcification.

Kidney & Blood Pressure Research 2018
Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney Function and Alkaline Phosphatase Profile in Patients with Chronic Kidney Disease.

Kidney International Reports 2018
Benefit of Apabetalone on Plasma Proteins in Renal Disease. 

American Journal of Cardiovascular Drugs 2017
Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease.

Molecular Pharmacology 2017
RVX-297, a BET bromodomain inhibitor, has therapeutic effects in preclinical models of acute inflammation and autoimmune disease.

Journal of Cardiovascular Translational Research 2017
Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208).

Atherosclerosis 2016
RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease.

Metabolism 2016
Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial.

Expert Opinion on Investigational Drugs 2015
An evaluation of RVX-208 for the treatment of atherosclerosis.

European Biopharmaceutical Review 2015
New Direction.

Atherosclerosis 2014
A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice.

PLoS One 2013
RVX-208, an Inducer of ApoA-I in Humans, is a BET Bromodomain Antagonist.


AHA Scientific Sessions 2018
Apabetalone (RVX-208) Suppresses Expression of Key Vascular Inflammation Markers in Monocytes, Endothelial Cells and LPS-Challenged Mouse Liver and Monocyte Adhesiveness to Activated Endothelial Cells

AHA Scientific Sessions 2018
Cardiovascular Evaluation of the Selective Bet Inhibitor, Apabetalone, in ACS Patients With Diabetes: Baseline Characteristics of the BETonMACE CV Outcomes Study

American Society of Nephrology (ASN) Kidney Week 2018
Apabetalone Downregulates Factors and Pathways Associated with Vascular Calcification

Clinical Trials on Alzheimer's Disease Conference (CTAD) Barcelona 2018
Apabetalone, a BET Bromodomain Inhibitor, Suppresses Inflammatory Mediators in Microglia and Vascular Endothelial Cells that Contribute to Neurodegenerative Disease

Clinical Trials on Alzheimer's Disease Conference (CTAD) Shanghai 2018
Effect of the BET Protein Inhibitor Apabetalone on Serum Markers of Potential Importance for Cognitive Decline in Cardiovascular Disease Patients

Alzheimer's Association International Conference (AAIC) 2018
Apabetalone (An Epigenetic BET-Inhibitor Small Molecule): A Substudy Evaluating Effects on Cognition in Diabetes Patients with Cardiovascular Disease

European Renal Association European Dialysis and Transplant Association (ERA-EDTA) Congress 2018
BETonMACE Chronic Kidney Disease Sub-Study: Effects of the Selective BET-Inhibitor Apabetalone on Kidney Function and MACE in Post-ACS Patients with Diabetes and Estimated Glomerular Filtration Rate Below 60. 

European Renal Association European Dialysis and Transplant Association (ERA-EDTA) Congress 2018
Inhibition of BET Proteins with Apabetalone Reduces Mediators of Vascular Calcification In Vitro and in CKD Patients. 

American Diabetes Association Scientific Sessions 2017
Apabetalone (RVX-208) Lowers Major Adverse Cardiovascular Events (MACE) in Diabetes Mellitus by Affecting Complement Pathway and Microbiome Activity. 

European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress 2017
Effects of Apabetalone (RVX-208) on Serum Albumin in Subjects with CVD, Diabetes and Chronic Kidney Disease; a Post-Hoc Analysis of the ASSURE and SUSTAIN Clinical Trials. 

European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress 2017
Apabetalone, A Bromodomain and Extraterminal Protein Inhibitor, Decreases Key Factors in Vascular Calcification in Vitro and in Clinical Trials. 

International Conference on Alzheimer's & Parkinson's Diseases 2017
Apabetalone, a BET Bromodomain Inhibitor, Suppresses Inflammatory Mediators in Microglia that Contribute to Neurodegenerative Disease.

Atherosclerosis, Thrombosis & Vascular Biology Scientific Sessions 2017
Apabetalone (RVX-208), a Selective CET Protein Inhibitor, Reduces Expression of Acute Phase Response Markers in Vitro and In Patients with Cardiovascular Disease and Chronic Kidney Disease.

American Society of Nephrology Conference 2016
Apabetalone Reduces Levels of Key Markers Involved in Vascular Calcification. 

American Heart Association Scientific Sessions 2016
Apabetalone (RVX-208) Reduces Expression of Acute Phase Response Markers in Vitro and in Patients with Cardiovascular Disease.

European Society of Cardiology Congress 2016
Modulation of the Complement Cascade in Cardiovascular Disease Patients by a Bromodomain and Extraterminal (BET) Protein Inhibitor. 

Atherosclerosis, Thrombosis & Vascular Biology Scientific Sessions 2016
Apabetalone (RVX-208) has Anti-Atherosclerotic, Anti-Thrombotic and Anti-Inflammatory Effects in Patients with Cardiovascular Disease. 

American Heart Association Scientific Sessions 2015
RVX-208, a Selective Bromodomain Extra-Terminal (BET) Protein Inhibitor, Acts on Several Pathways to Benefit Cardiovascular Risk. 

American Society of Nephrology Conference 2015
Alkaline Phosphatase Lowering by Selective BET Inhibition, a Novel Mechanism for MACE Reduction in High Risk CVD, Diabetes and CKD Patients; a Post-hoc Analysis of Phase 2b Studies with Apabetalone (RVX-208).

American Society of Nephrology Conference 2015
Apabetalone (RVX-208), a First-in-Class Epigenetic BET Inhibitor, has Effects on ALP and eGFR in Subjects with CVD and CKD; a Post-hoc Analysis of ASSERT, SUSTAIN and ASSURE Clinical Trials.


Haarhaus et al. 2017 
Alkaline Phosphatase: A Novel Treatment Target For Cardiovascular Disease in CKD

Ridker et al. 2017
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Campbell et al. 2017
BET Bromodomain Inhibitors and Agonists of the Beta-2 Adrenergic Receptor Identified in Screens for Compounds That Inhibit DUX4 Expression in FSHD Muscle Cells

Hwang et al. 2017
NF-κB as a Key Mediator of Brain Inflammation in Alzheimer’s Disease

Hill et al. 2017
Paroxysmal Nocturnal Haemoglobinuria

Najafova et al. 2017
BRD4 Localization to Lineage-Specific Enhancers is Associated with a Distinct Transcription Factor Repertoire

Suarez-Alvarez et al. 2016
Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage

Xiong et al. 2016
Pharmacological Targeting of BET Proteins Inhibits Renal Fibroblast Activation and Alleviates Renal Fibrosis

Hollander et al. 2015
Gender-Specific Plasma Proteomic Biomarkers in Patients with Anderson–Fabry Disease

Meloche et al. 2015
Bromodomain-Containing Protein 4: The Epigenetic Origin of Pulmonary Arterial Hypertension

Patel el al. 2014
BET Bromodomain Inhibition Triggers Apoptosis of NF1-Associated Malignant Peripheral Nerve Sheath Tumors through Bim Induction

White et al. 2013
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
Mottillo et al. 2010
The Metabolic Syndrome and Cardiovascular Risk
Tonelli et al. 2009
Relation Between Alkaline Phosphatase, Serum Phosphate, and All-Cause or Cardiovascular Mortality

Blayney et al. 2008
High Alkaline Phosphatase Levels in Hemodialysis Patients are Associated with Higher Risk of Hospitalization and Death
Barter et al. 2007
HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events
Walldius et al. 2001
High Apolipoprotein B, Low Apolipoprotein A-I, and Improvement in the Prediction of Fatal Myocardial Infarction (AMORIS study): A Prospective Study